scholarly journals Using bioresonance therapy in treatment of patients with hypothyroidism

2016 ◽  
Vol 97 (4) ◽  
pp. 545-550
Author(s):  
V V Kiryanova ◽  
N V Vorokhobina ◽  
Z H Makhramov
Keyword(s):  
Placebo Group ◽  
Targeted Therapy ◽  
Hormone Replacement ◽  
Combined Treatment ◽  
Thyroid Stimulating Hormone ◽  
Main Group ◽  
High Density Lipoproteins ◽  
Control Group ◽  
Bioresonance Therapy ◽  
Basic Treatment

Aim. To evaluate the effectiveness of using bioresonance therapy in the treatment of patients with hypothyroidism.Methods. Three matched groups of patients with acquired hypothyroidism consisting of 50 people aged 20 to 60 years (mean age 45.6 years) were included in a study. All patients were treated by the same conventional scheme of treatment of hypothyroidism: thyroid hormone replacement drugs. The main group, in addition to replacement therapy received bioresonance therapy. The second group (control) received only pharmacotherapy, the third group (placebo) received pharmacotherapy and simulation of bioresonance therapy procedures. Patients of the main group received 12 daily bioresonance therapy procedures using «Det Professional» device, consisting of two stages: the basic treatment stage and targeted therapy stage. 5 procedures of basic treatment and 7 procedures of targeted therapy were performed.Results. After bioresonance therapy, free thyroxine fraction value in the main group significantly increased in comparison with the control group and the placebo group. Values of thyroid-stimulating hormone after the conducted therapy in the main group significantly decreased compared with the control group and the placebo group. The lipidogram results indicate that the content of high-density lipoproteins in the study group significantly increased compared with the control group and the placebo group. The concentrations of low-density lipoproteins, cholesterol and triglycerides in the main group became significantly lower than in the control group and the placebo group.Conclusion. The obtained results give the evidence of the effectiveness of using bioresonance therapy in combined treatment of patients with hypothyroidism and in achieving stable remission of hypothyroidism.

scholarly journals Blood antioxidant capacity change in patients with the «dry» form of age-related macular degeneration treated with polarized polychromatic non-coherent light and dynamic electromyostimulation

2012 ◽  
Vol 93 (6) ◽  
pp. 994-996
Author(s):  
F R Saifullina ◽  
R Z Sharafieva ◽  
V I Pogorel’tsev ◽  
F M Fayzrahmanova ◽  
E A Abdulaeva
Keyword(s):  
Visual Acuity ◽  
Antioxidant Capacity ◽  
Macular Degeneration ◽  
Combined Treatment ◽  
Mean Value ◽  
Main Group ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Coherent Light ◽  
Age Related

Aim. To assess the antioxidant capacity in patients with the «dry» form of age-related macular degeneration before and after combined treatment with polarized polychromatic non-coherent light and dynamic electromyostimulation. Methods. Two groups of patients with the «dry» form of age-related macular degeneration were examined. 40 patients (80 eyes) from the main group were treated using combined treatment and 39 patients (78 eyes) in the group of control who were treated conventionally. The integral blood antioxidant capacity was measured by galvanometry. Results. Blood antioxidant capacity in healthy subjects is 26.0 kC/l. In patients of the main group blood antioxidant capacity before the treatment was equal to 22.81±0.27 kC/l, compared to 22.17±0.20 kC/l in control group (total mean value 22.49±0.27 kC/l). There was a relevant elevation of the blood antioxidant capacity at the late stages after the treatment - up to 12 months, compared to only 2 months in the control group. Visual acuity in patients of the main group before the treatment was 0.87±0.02, after the treatment was finished - 0.96±0,01 (p 0.001), 2 months after the treatment - 0.95±0.01 (p 0.001), 6 months after the treatment - 0.96±0.01 (p 0.001), 12 months after the treatment - 0.95±0.01 (p 0.001). Visual acuity in patients of the control group before the treatment was 0.91±0.02, after the treatment was finished - 0.95±0.02 (p 0.05), 2 months after the treatment - 0.94±0.02 (p 0.05), 6 months after the treatment - 0.92±0.02 (p 0.05). 12 months after the treatment the visual acuity deteriorated compared to the treatment start and was measured as 0.89±0.02. Conclusion. There is a decrease of blood antioxidant capacity (22.49±0.27 kC/l) in patients with the «dry» form of age-related macular degeneration; a relevant increase of blood antioxidant capacity and visual acuity can be observed up to 12 months after the treatment with polarized polychromatic non-coherent light and dynamic electromyostimulation.

Safety assessment of preoperative oil chemoembolization with nanoparticle albumin-bound paclitaxel in patients with pancreatic head adenocarcinoma

2020 ◽  
Vol 22 (4) ◽  
pp. 67-71
Author(s):  
A. V. Pavlovskii ◽  
A. A. Statsenko ◽  
S. A. Popov ◽  
V. E. Moiseenko ◽  
A. A. Polikarpov
Keyword(s):  
Preoperative Chemotherapy ◽  
Combined Treatment ◽  
Pancreatic Head ◽  
Main Group ◽  
Ductal Adenocarcinoma ◽  
Control Group ◽  
Postoperative Pancreatitis ◽  
Body Level ◽  
Degree Of Severity ◽  
Group Grade

Results of combined treatment of 36 patients suffering from pancreatic head ductal adenocarcinoma are evaluated, including preoperative chemotherapy using nanodispersed albumin-stabilized paclitaxel (nab-paclitaxel) in intraarterial oil chemoembolization or intravenous administration and radical surgical treatment. Intraarterial oily chemoembolization of the pancreatic head consisted of the introduction of 17 patients (main group) into the gastroduodenal artery of an emulsion of super-liquid lipiodol (Lipiodol Ultra Fluid) in an aqueous solution of nab-pacliaxel 50 mg/m2 and gemcitabine 400 mg/m2. 19 patients (control group) were administered nab-paclitaxel 100 mg/m2 and gemcitabine 1000 mg/m2 intravenously according to standard guidelines. Safety and tolerability assessment of combined treatment with preoperative application of nab-paclitaxel was carried out in advance. Pil-preserving pancreatoduodenal resection is considered safe on day 710, after completion of preoperative chemotherapy with nab-paclitaxel. The use of nab-paclitaxel in preoperative intraarterial oily chemoembolization of the pancreatic head requires extension of the pancreatic crossing boundary to body level. Postoperative lethality and 4th degree complications according to the Clavien-Dindo classification were not observed. In the main group, grade 3a complication was observed in 2 (12%) patients and was represented by bleeding from acute gastric erosions resolved endoscopically. In the control group, complications of degree 3 were also noted in 2 (11%) patients and were represented by: one bleeding from acute stomach erosions that required endoscopic hemostasis and an intraabdominal abscess allowed by percutaneous drainage. In the main group, complications of the 2nd degree were recorded in 8 (47%) patients: in 3 (17%) patients the formation of pancreatic fistula was noted, in 4 (23%) postoperative pancreatitis was detected, and in 1 (6%) gastrostasis phenomena that required conservative therapy. In the control group, complications of the 2nd degree were observed in 11 (58%) patients and were presented: pancreatic fistulae in 2 (10%) patients, postoperative pancreatitis in 6 (31%) and gastrostasis in 3 (16%) patients. The most common complication observed in both groups was the suppression of a postoperative wound, corresponding to the 1st degree of severity: in the main group in 5 (29%) patients, in the control group in 7 (37%) patients. Thus, the use of intraarterial oil chemoembolization with nab-paclitaxel as a preoperative antitumor treatment can be considered safe.

scholarly journals Еfficacy of Combined Treatment of Epithelial and Endothelial Corneal Dystrophy Using Corneal Crosslinking and Automated Posterior Lamellar Keratoplasty

2019 ◽  
Vol 16 (1S) ◽  
pp. 102-107
Author(s):  
L. R. Marvanova
Keyword(s):  
Surgical Treatment ◽  
Combined Treatment ◽  
Corneal Thickness ◽  
Corneal Edema ◽  
Corneal Dystrophy ◽  
Main Group ◽  
Stage I ◽  
Lamellar Keratoplasty ◽  
Control Group ◽  
Posterior Lamellar Keratoplasty

The purpose: to establish a combined approach to the treatment of patients with epithelial and endothelial cornea dystrophy (EED) based on a comparative study of the results of one-step and two-step methods. Patients and methods. The study included 75 patients (81 eyes) with corneal EED, who underwent surgical treatment at the Ufa Eye Research Institute from 2011 to 2016. The patients were divided into two groups — the main group consisted of 43 (46 eyes, 57 %) patients, who underwent the first stage of the CC before surgical treatment of EED, the second stage after 1–12 months — automated posterior lamellar keratoplasty (APLK). In the control group, isolated APLK was performed in 32 (35 eyes, 43 %) patients. Results. After CC (1–10 days) in the main group an increase in corneal thickness due to edema enhancement in the cornea stroma was observed in patients with stage I–III of the corneal EED. After 3 months, a decrease in corneal thickness was recorded in patients of the main group with I-II stages of the disease (p < 0.05), after 6 months — in all stages of the corneal EED compared with the control group (p < 0.05). According to optical coherence tomography (OCT), a decrease in the total cornea thickness in both зфешутеы groups was noted within 12 months after APLK: in the main group from 667 ± 65 μm initially to 594 ± 31 μm, in the control group, where there was a pronounced corneal edema from 787 ± 56 to 612 ± 67 μm. Conclusion. Corneal cross-linking in patients with I–III stages of corneal EED provides improvement of the cornea, manifested in reducing edema and its thickness. It allows to delay the implementation of the automated posterior lamellar keratoplasty without corneal deterioration in patients with stage I up to 6–12 months, in patients with stage II–III up to 3–6 months.

scholarly journals The Use of Radiofrequency Thermal Ablation in Combine Treatment of Patients with Liver Bilobar Metastases from Colorectal Cancer

2018 ◽  
Vol 3 (2) ◽  
pp. 49-53
Author(s):  
OI I Kaganov ◽  
SV V Kozlov ◽  
AE E Orlov ◽  
NV V Blinov
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Combined Treatment ◽  
Treatment Method ◽  
Main Group ◽  
Rank Test ◽  
Control Group ◽  
Metastatic Process ◽  
Oncology Centre

Aim - determination of RFTA place in the combined treatment of bilobar liver metastatic process of colorectal cancer. Materials and methods. 176 patients with colorectal cancer with multiple (more than 4) bilobar liver metastases were included in the study after primary tumor removal. The research was held in Samara Regional Oncology Centre from 2001 to 2014. According to the treatment method patients were divided into two groups. Main group got the combined (chemotherapy + RFTA) treatment (98 patients). In control group only chemotherapy was applied to 78 patients. Results. One-, two- and three-year OS were 73.5%, 25.1%, 7.2% in the main group and 39.6%, 6.3%, 2.1% in the control group. With RFTA application we reached the 1.8% index of four-year survival in the main group, while three-year survival in the control group was only 2.1%. The OS median reached 18 months in the main group and 11 months in the control group, OS curves in two comparing groups were significantly different( log-rank test 3.77, р=0,000). Conclusion. Combination of RFTA with chemotherapy as the treatment of bilobar liver metastases of colorectal cancer, significantly improves the DFS and overall survival indexes, comparing to the group of patients who received only chemotherapy.

Experience of Optimization of Medical Care for Women in Menopause with Dry Eye Syndrome

2021 ◽  
pp. 31-35
Author(s):  
A.S. Obrubov ◽  
◽  
Keyword(s):  
Medical Care ◽  
Dry Eye ◽  
Combined Therapy ◽  
Combined Treatment ◽  
Low Frequency ◽  
Main Group ◽  
Dry Eye Syndrome ◽  
Control Group ◽  
Treatment Technology ◽  
Complex Preparation

Purpose. Optimization of medical care for women in menopause with dry eye syndrome from the standpoint of experimental and clinical substantiation of combined technologies. Material and methods. The studies were carried out on a group of 72 patients (144 eyes) in the postmenopausal period with dry eye syndrome. The average age of women was 54.4±3.3 years. All patients, depending on the therapy, were divided into two groups. The first group (control) consisted of 34 women (68 eyes) who received only local daily monotherapy for 20 days – instillation of low-viscosity «artificial tear» preparations HyloComod. Patients of the main group were divided into 2 subgroups and used a combined treatment technology. The first subgroup consisted of 21 patients (42 eyes), who, in addition to local daily therapy of the above drug, received a suis-organ complex preparation of estrogen-like orientation Ovarium compositum once every 3 months. The second subgroup included 17 patients (34 eyes) who received a treatment technology that included local daily therapy with artificial tears in combination with courses (once every 3 months) of exposure to the head area by a pulsed low-frequency electromagnetic field in combination with suis-organ complex preparation of estrogen-like orientation Ovarium compositum. Results. The combined treatment technology was well tolerated in all examined women. There were no complications or side effects. A significant increase in the main tear production in women of the main group made it possible to achieve a significantly more pronounced decrease in symptoms of subjective discomfort than in women in the control group. The achieved results of treatment of women in the main group persisted for 2.5–3 months, which determined the frequency of the courses of combination therapy with a frequency of twice every 6 months during the subsequent observation period. Conclusion. The course of combined therapy makes it possible to achieve significant relief of subjective manifestations of dry eye syndrome in postmenopausal women. The implementation of the therapeutic effect occurs, apparently, due to the synergism of the natural factors used, which makes it possible to significantly activate the compensatory and adaptive processes in the meibomian glands. Key words: dry eye syndrome of climacteric origin, combined treatment technology, estrogen deficiency, sex hormones.

Effect of Intravenous Laser Irradiation of Blood on the Dynamics of Glycosaminoglycans in the Serum of Patient with Rheumatoid Arthritis

10.12737/5759 ◽  
2014 ◽  
Vol 8 (1) ◽  
pp. 1-4
Author(s):  
Бурдули ◽  
N. Burduli ◽  
Бурдули ◽  
N. Burduli
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Therapy ◽  
Laser Irradiation ◽  
Combined Treatment ◽  
Main Group ◽  
Control Group ◽  
Group Level ◽  
American College Of Rheumatology ◽  
Traditional Drug ◽  
Conventional Medical Therapy

The purpose of this work is to study the content of glycosaminoglycans in the serum of patients with rheumatoid arthritis and their dynamics in complex therapy of intravenous laser irradiation of blood. Materials and methods: 102 patients with a diagnosis of rheumatoid arthritis were examined. Diagnosis was made according to the criteria ACR/EULAR (American College of Rheumatology/European League Against Rheumatism 2010г.). All patients were divided into two groups: basic and control. In the control group, patients received only traditional drug therapy. The main group consisted of patients who received conventional medical therapy in addition, the course of intravenous laser therapy. Results. Before treatment the level of glycosaminoglycans was significantly higher than the norm and made up in the main group 0,718±0,069 g/l (p&#60;0,01), in the control group level amounted to 1,048±has 0.168 g/l (p&#60;0,01). After treatment only in the main group level of glycosaminoglycans decreased significantly to values ​​of the norm, making 0,410±0,032 g / l (p&#60;0,001). The control group didn’t decrease in glycosaminoglycans reached standards (0,799±0,138 g / l) and was not statistically significant (p&#62;0,05). Conclusions: The use of intravenous laser irradiation of blood in rheumatoid arthritis patients in the combined treatment with conventional drug therapy allows to normalize the level of glycosaminoglycans in the serum.

scholarly journals THE CHARACTERISTICS OF BLOOD LIPIDS OF MENOPAUSAL WOMEN WITH THE COMPENSATED HYPOTHYROIDISM WHICH RESULTS FROM AUTOIMMUNE THYROIDITIS

2014 ◽  
Vol 13 (2) ◽  
pp. 14-20
Author(s):  
Yu. A. Malyshenko ◽  
O. D. Rymar ◽  
M. V. Ivanova ◽  
L. V. Shcherbakova ◽  
S. F. Zhinchyk
Keyword(s):  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Hashimoto Thyroiditis ◽  
High Density ◽  
High Density Lipoproteins ◽  
Control Group ◽  
Mean Values ◽  
Menopausal Women ◽  
The Difference ◽  
And Control

Purpose: to study the lipid profile, including of non-high-density lipoproteins cholesterol (non-HDL-C), in postmenopausal women with compensated hypothyroidism. The causes of hypothyroidism included Hashimoto thyroiditis.45 women with hypothyroidism participated in the study (mean ± sd, age (57.4 ± 7.7) years, disease duration (8.0 ± 6.4) years, the duration of postmenopause (6.4 ± 3.5) years). The mean dose of L-T4 (84.3 ± 28.5) μg/d. The control group – 85 women (mean ± sd, age (58.4 ± 5.4) years) no abnormalities of the thyroid gland, as well as other chronic diseases, which could have an impact on lipid metabolism.The main and control group were matched for age. Average BMI basic group than in controls: (31.6 ± 3.4) and (28.7 ± 4.6) kg/m2 respectively (p = 0.001). Obtained statistical differences in terms of TSH in the study and control groups: 2.15 and 1,22 mU/L (p = 0.001). Upon reaching euthyrosis against the background of hormone replacement therapy with thyroid hormones do not reach the target total cholesterol (TC), low density lipoproteins cholesterol (LDL-C): 5.81 ± 1.14, 3.67 ± 1.06 respectively.We obtain lower high-density lipoproteins cholesterol (HDL-C) levels in women with drug euthyroidism compared with the control group. Do not get the difference in the values non-HDL-C in the groups studied. In postmenopausal women with compensated hypothyroidism is defined negative correlation ATTPO with HDL-C. Mean values of blood TC, non-HDL-C, LDL-C levels in the groups exceed the optimal ones.

scholarly journals GOUT AND ARTERIAL HYPERTENSION: THERAPY PECULIARITIES

2020 ◽  
Vol 20 (1) ◽  
pp. 100-105
Author(s):  
V.М. Zhdan ◽  
V.G. Lebid ◽  
H.S. Кhaimenova ◽  
G.A. Isheikina
Keyword(s):  
Uric Acid ◽  
Arterial Hypertension ◽  
Combined Therapy ◽  
Study Groups ◽  
Main Group ◽  
High Density Lipoproteins ◽  
Professional Activity ◽  
Control Group ◽  
Uric Acid Concentration ◽  
Clinical Effects

The article highlights the issues on comorbidity between gout and hypertension. Emphasis is placed on the necessity in searching for a well-balanced approach toward the treatment this type of comorbidity. Gout is a major social and economic problem in the modern society that leads to a progressive physical incapability, limitation of professional activity, thus impairing the quality of life. Arterial hypertension occurs in patients with gout in 5 - 50% of cases, and in combination with components of metabolic syndrome its prevalence rises up to 80%. As a result, the development of hypertension in patients with gout leads to a deterioration of the kidney functioning due to the combination of two pathological conditions for which the kidneys are either functioning organs or target organs. Management of arterial hypertension by general practitioner requires the searching for the most optimal approach in using metabolically neutral antihypertensives to avoid provoking medication-induced exacerbation of arthritis. In addition, the treatment of such category of patients should also provide the optimal nephroprotective effect and decrease the uric acid concentration in the serum that will contribute to the additional prevention of gout attacks. The aim of the study is to evaluate the nephroprotective, antihypertensive, hypolipidemic effects of the proposed combined therapy in the patients with comorbidity between gout arthritis and arterial hypertension. The study was conducted at the Regional Medical and Diagnostic Centre of Rheumatological Diseases, M.V. Sklifosovskyi Poltava Regional Clinical Hospital, which is the clinical base of the Department of Family Medicine and Therapy, Ukrainian Medical Stomatological Academy. 60 patients with mean age of 54.2 ± 8.6 years were enrolled to the study. The patients suffering from gout arthritis and comorbid hypertension formed the main group. The control group consisted of 60 patients matched by age, demographic and clinical parameters. Following the 12-month treatment period, we have registered clinical effects of the combination therapy proposed in patients with gout and comorbid hypertension. We observed a decrease in blood lipids values in the study groups: total cholesterol decreased by 16.0% in the main group and by 8.0% in the control group, high-density lipoproteins – by 5.6% in the main group and by 6.4% in the control group, low density lipoproteins – by 3.3% in the main group and by 3.4% in the control group, triglycerides – by 22.2% in the main group and 12.3% in the control group. We observed statistically significant improvement in the glomerular filtration rate in the main group (6.4% of cases vs. 1.3% in the control group). The blood creatinine in the both study groups decreased significantly. The uric acid blood concentration decreased by 32.6% in the main group compared to 24.6% in the control group. During the six month period of the therapy the necessity for non-steroidal anti-inflammatory drugs cut down by 58% in the study group vs. 37% in the control group. Conclusions. After 12 month period of therapy proposed, the patients with gout and comorbid hypertension demonstrated clinically confirmed improvement in both study groups (87.7% of patients in the main group vs. 48.6% in the control group). The efficacy of the proposed treatment was assessed by physicians up to 87%, vs.  88% efficacy assessed by the patients in the main group.

Three-year survival after combined treatment with induction chemoimmunotherapy in patients (pts) with non-small cell lung cancer (NSCLC).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e20064-e20064
Author(s):  
Yuriy N. Lazutin ◽  
Sergey P. Pyltsin ◽  
Anna Pavlovna Kharitonova ◽  
Tamara G. Ayrapetova ◽  
Igor A. Leyman ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Radical Surgery ◽  
Combined Treatment ◽  
Main Group ◽  
Control Group ◽  
Kaplan Meier ◽  
And Control ◽  
Direct Results ◽  
Recombinant Tumor Necrosis Factor ◽  
Necrosis Factor

e20064 Background: Induction chemotherapy (iCT) for NSCLC has potential advantages over adjuvant CT, high therapeutic compliance, the ability to influence the primary tumor and metastatic disease. Standard approaches to iCT improving are largely exhausted. However, the development of iCIT techniques using recombinant cytokines and assessment of the effectiveness of its clinical application remains poorly understood. Methods: Clinical trial included 65 pts. with stage IIB, IIIA (N2), IIIB (T4 ipsi. nod.) NSCLC, randomized in main (n = 33) and control (n = 32) groups with comparable clinical and pathological characteristics: m 23 (69.7) vs. 23 (71.8%), W 10 (30,3%) vs. 9 (28.2%); stage IIB - 8 (24.4%) vs. 9 (28.6%), IIIA - 22 (66.6%) vs. 19 (59.4%), IIIB - 3 (9%) vs. 4 (12.5%); 40-49 years 5 (15,5%) vs. 5 (15,6%), 50-59 14 (42,4%) vs.15 (46,8%), 60 years and older 14 (42,4%) vs. 12 (37,8%). Pts. of the control group received 2 iCT cycles: cisplatin 75 mg / m2 i.v. 1 day and gemcitabine 1000 mg / m2 i. v. 1 and 8 days; pts. of the main group additionally received recombinant tumor necrosis factor coupled with thymosin (TNF-T Farmaclon Russia) 50. 000 ED / m2i.v. 3, 5 and 7 days of the cycle. The direct results were evaluated 3 weeks after completion of induction. Pts. who underwent radical surgery received 2 cycles of platinum-based adjuvant CT. DFS was studied by the method of Kaplan-Meier. Results: 3-year DFS in the main group was 72% vs. 48% in the control group (p = 0.10603). Conclusions: Clinical trial of the effectiveness of iCIT with using immune drug TNF-T demonstrated a tendency to improve 3-year DFS by 24%, which favors further studies on a larger number of pts.

scholarly journals EFFICIENCY OF TREATMENT OF INFLAMMATORY PERIODONTAL DISEASES IN PREGNANT WOMEN

2021 ◽  
Vol 74 (5) ◽  
pp. 1065-1068
Author(s):  
Nataliia G. Gadzhula ◽  
Olena L. Cherepakha ◽  
Olena V. Lezhnova
Keyword(s):  
Pregnant Women ◽  
Oral Hygiene ◽  
High Efficiency ◽  
Periodontal Diseases ◽  
Group Versus ◽  
Main Group ◽  
Control Group ◽  
Periodontal Tissues ◽  
Prophylactic Measures ◽  
Basic Treatment

The aim: To study the clinical efficciency of the proposed scheme of gingivitis treatment in women with physiological course of pregnancy. Materials and methods: Clinical approbation of the proposed complex of therapeutic and prophylactic measures was carried out in 32 pregnant women with gingivitis, aged 18 to 35 years. The efficiency of the treatment was assessed by the dynamics of the clinical picture, the index assessment of an oral hygiene and the periodontium condition in each trimester of pregnancy. Results: According to the data of performed observations, the high efficiency of the proposed treatment scheme is shown: 84.4% in the main group versus 46.9% in the control group. It has been clinically proven that the proposed scheme of inflammatory periodontal diseases treatment in terms of therapeutic efficiency exceeds the generally accepted basic treatment. Conclusions:The use of the proposed complex of therapeutic and prophylactic measures in the main group of patients contributed to the elimination of the inflammatory process in the periodontal tissues, suspended the progression of existing diseases, made it possible to prevent the emergence of new nosological forms, improved the condition of the oral hygiene, which makes it possible to recommend it for treatment of periodontal diseases in pregnant women.

Sign in / Sign up

Export Citation Format

Share Document